source
- Vertex reports positive Phase 2b results for inaxaplin in APOL1-mediated kidney diseaseVertex Pharmaceuticals announced positive Phase 2b data for its kidney disease candidate inaxaplin, which targets APOL1-mediated kidney disease (AMKD). The Amplified trial enrolled two cohorts: 2…
- Viking Therapeutics reports obesity drug maintains weight loss after dosing switch, shares jump 36%Viking Therapeutics said its Phase 2 trial of the dual-acting obesity candidate VK2735 showed participants largely kept the weight they had lost when the dosing schedule changed from a weekly injec…